Business
Hyderabad startup Helex targets kidney gene editing
Livemint·
Hyderabad biotech Helex Inc, founded by three King's College graduates, is developing genetic medicines to deliver drugs to kidney cells. Chief executive Poulami Chaudhuri said the firm has filed four patents. Its lead program targets autosomal dominant polycystic kidney disease using lipid nanoparticles. The candidate has not yet entered human clinical trials, the founders said.
Prism
What It Means For You
- Indian ADPKD patients may eventually access locally developed gene therapies if Helex clears future clinical trials.
- Helex founders met in London in 2009 and later built lipid nanoparticle delivery for kidney gene editing in Hyderabad.
- They cited crowdfunding costs for rare disease drugs as motivation.
What's Happening
- Helex founders met in London in 2009 and later built lipid nanoparticle delivery for kidney gene editing in Hyderabad.
- They cited crowdfunding costs for rare disease drugs as motivation.
- Helex said no therapy has yet reached kidney cells safely; its lead ADPKD program remains pre-clinical despite mouse and primate delivery data.
Gene editing delivery to kidneys
- Helex said no therapy has yet reached kidney cells safely; its lead ADPKD program remains pre-clinical despite mouse and primate delivery data.
- Helex founders met in London in 2009 and later built lipid nanoparticle delivery for kidney gene editing in Hyderabad.
- They cited crowdfunding costs for rare disease drugs as motivation.
all-news